Safety Profile of Lithium: A Disproportionality Analysis Using the FDA Adverse Event Reporting System
Neuropsychobiology · 2025
DOI: 10.1159/000546602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychobiology, 2025. Verfasst von Hao Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, China, zhuhao24…. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Pharmacovigilance, Lithium Compounds, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Although lithium has long been considered the gold standard for mood stabilization in the treatment of bipolar disorder, growing concerns about its adverse events have significantly undermined its once-trusted status. This study aims to conduct a pharmacovigilance analysis of lithium to provide a more comprehensive understanding of its safety profile.
Methods
Four disproportionality analysis methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM), were employed to detect potential signals between lithium and various adverse events.
Results
Analysis of 6,909 adverse event reports from the FDA Adverse Event Reporting System (FAERS) showed that lithium-related adverse events occur in the endocrine, renal or urinary, nervous, and psychiatric systems. Well-known adverse events, such as hypothyroidism, nephrogenic diabetes insipidus, and ataxia, were found. In addition, several previously overlooked adverse events, such as renal oncocytoma, benign parathyroid tumor, and Adams-Stokes syndrome, were identified.
Conclusion
By analyzing real-world data, this study provides a comprehensive evaluation of lithium’s safety profile, offering critical evidence for its clinical risk. However, given the inherent limitations of FAERS, such as underreporting of minor symptoms, the findings should be interpreted cautiously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, China, zhuhao24@connect.hku.hk.
- Department of Health and Kinesiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
- Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, China.
Zitieren
APA
Zhu, H., Guo, J., Lui, H., & Ip, P. (2025). Safety Profile of Lithium: A Disproportionality Analysis Using the FDA Adverse Event Reporting System. Neuropsychobiology. https://doi.org/10.1159/000546602
Vancouver
Zhu H, Guo J, Lui H, Ip P. Safety Profile of Lithium: A Disproportionality Analysis Using the FDA Adverse Event Reporting System. Neuropsychobiology. 2025. doi:10.1159/000546602
BibTeX
@article{Zhu2025,
author = {Zhu, Hao and Guo, Jack and Lui, Hannah and Ip, Patrick},
title = {Safety Profile of Lithium: A Disproportionality Analysis Using the FDA Adverse Event Reporting System},
journal = {Neuropsychobiology},
year = {2025},
doi = {10.1159/000546602}
}
EUVIMED